BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31938638)

  • 1. PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors.
    Wang JJ; Burger P; Taube J; Soni A; Chaichana K; Sheu M; Belcaid Z; Jackson C; Lim M
    Cureus; 2019 Dec; 11(12):e6352. PubMed ID: 31938638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma.
    Kamamoto D; Ohara K; Kitamura Y; Yoshida K; Kawakami Y; Sasaki H
    J Neurooncol; 2018 Sep; 139(2):251-259. PubMed ID: 29675794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LAG-3, TIM-3 and VISTA Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma-Potential Biomarkers for Targeted Therapy Concepts.
    Wuerdemann N; Pütz K; Eckel H; Jain R; Wittekindt C; Huebbers CU; Sharma SJ; Langer C; Gattenlöhner S; Büttner R; Speel EJ; Suchan M; Wagner S; Quaas A; Klussmann JP
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.
    El Halabi L; Adam J; Gravelle P; Marty V; Danu A; Lazarovici J; Ribrag V; Bosq J; Camara-Clayette V; Laurent C; Ghez D
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):257-266.e3. PubMed ID: 33277223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases.
    Lu BY; Gupta R; Aguirre-Ducler A; Gianino N; Wyatt H; Ribeiro M; Chiang VL; Contessa JN; Adeniran AJ; Jilaveanu LB; Kluger HM; Schalper KA; Goldberg SB
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34670827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
    Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
    J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.
    Kreidieh FY; Tawbi HA
    Ther Adv Med Oncol; 2023; 15():17588359231186027. PubMed ID: 37484526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain.
    Herrera-Rios D; Mughal SS; Teuber-Hanselmann S; Pierscianek D; Sucker A; Jansen P; Schimming T; Klode J; Reifenberger J; Felsberg J; Keyvani K; Brors B; Sure U; Reifenberger G; Schadendorf D; Helfrich I
    Front Immunol; 2020; 11():120. PubMed ID: 32117271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological and prognostic significance of PD-L1 and TIM-3 expression in medullary thyroid carcinoma: a retrospective immunohistochemistry study.
    Wusiman D; Guo L; Li L; Zhang X; Zhao X; An Z; Huang Z; Zhang Y; Li Z; Ying J; Wei M; Li W; An C
    J Endocrinol Invest; 2024 Jan; 47(1):91-100. PubMed ID: 37464189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies.
    Gide TN; Paver EC; Yaseen Z; Maher N; Adegoke N; Menzies AM; Pires da Silva I; Wilmott JS; Long GV; Scolyer RA
    Oncoimmunology; 2023; 12(1):2261248. PubMed ID: 37808404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer.
    Al-Badran SS; Grant L; Campo MV; Inthagard J; Pennel K; Quinn J; Konanahalli P; Hayman L; Horgan PG; McMillan DC; Roxburgh CS; Roseweir A; Park JH; Edwards J
    J Pathol Clin Res; 2021 Mar; 7(2):121-134. PubMed ID: 33338327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune microenvironment of basal cell carcinoma and tumor regression following combined PD-1/LAG-3 blockade.
    Deutsch JS; Lai J; Schenk KM; Soni A; Will EM; Engle LL; Xu H; Ogurtsova A; Madan V; Chong JK; Wang D; Green BF; Nguyen P; Schollenberger MD; Lipson EJ; Taube JM
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38101862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion.
    Bruss C; Kellner K; Albert V; Hutchinson JA; Seitz S; Ortmann O; Brockhoff G; Wege AK
    Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic myofibroblasts exert immunosuppressive effects independent of the immune checkpoint regulator PD-L1 in liver metastasis of pancreatic ductal adenocarcinoma.
    Beckinger S; Daunke T; Aldag L; Krüger S; Heckl S; Wesch D; Schäfer H; Röcken C; Rahn S; Sebens S
    Front Oncol; 2023; 13():1160824. PubMed ID: 37207152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes.
    Ligon JA; Choi W; Cojocaru G; Fu W; Hsiue EH; Oke TF; Siegel N; Fong MH; Ladle B; Pratilas CA; Morris CD; Levin A; Rhee DS; Meyer CF; Tam AJ; Blosser R; Thompson ED; Suru A; McConkey D; Housseau F; Anders R; Pardoll DM; Llosa N
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma.
    Chen BJ; Dashnamoorthy R; Galera P; Makarenko V; Chang H; Ghosh S; Evens AM
    Oncotarget; 2019 Mar; 10(21):2030-2040. PubMed ID: 31007846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of PD-1, TIM-3, LAG-3 and BTLA in diffuse large B-cell lymphoma and its effect on prognosis].
    Liu XY; Yuan XL; Ma RJ; Xu H; Yang SW; Nie L; Zhang L; Hu AX; Li Z; Zhu ZM
    Zhonghua Yi Xue Za Zhi; 2020 Sep; 100(36):2846-2853. PubMed ID: 32988145
    [No Abstract]   [Full Text] [Related]  

  • 18. T-Cell Immunoglobulin Mucin 3 Expression on Tumor Infiltrating Lymphocytes as a Positive Prognosticator in Triple-Negative Breast Cancer.
    Byun KD; Hwang HJ; Park KJ; Kim MC; Cho SH; Ju MH; Lee JH; Jeong JS
    J Breast Cancer; 2018 Dec; 21(4):406-414. PubMed ID: 30607162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early transient suppression of immune checkpoint proteins T-cell immunoglobulin mucin-3 and programmed cell death-1 in peripheral blood lymphocytes after blastocyst transfer is associated with successful implantation.
    Zhang T; Zhu W; Zhao Y; Cheung WC; Liu Y; Chen X; Du Y; Leung KT; Chan YL; Wang CC; Laird S; Li TC
    Fertil Steril; 2020 Aug; 114(2):426-435. PubMed ID: 32199622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TIM-3 expression in breast cancer.
    Burugu S; Gao D; Leung S; Chia SK; Nielsen TO
    Oncoimmunology; 2018; 7(11):e1502128. PubMed ID: 30377566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.